Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.61 |
| ▸ | CES1 | P23141 | 4/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599609 | 1.00 | CES2 (0.61) | CES2CES1BCHEHPGDRXFP1 | |
| SCHEMBL11836782 | 0.85 | CES2 (0.57) | CES2CES1BCHEHPGDALB | |
| SCHEMBL9118756 | 0.85 | CES2 (0.47) | CES2CES1BCHEHPGDRXFP1 | |
| SCHEMBL1155949 | 0.83 | PTPN1 (0.58) | CES2CES1HPGDRXFP1PTPN1 | |
| SCHEMBL30036725 | 0.83 | PTPN1 (0.58) | CES2CES1HPGDRXFP1PTPN1 | |
| SCHEMBL24803066 | 0.82 | KAT6A (0.44) | CES2CES1BCHEHPGDPDK2 | |
| SCHEMBL4598039 | 0.82 | ALB (0.60) | CES2CES1BCHERXFP1ALB | |
| SCHEMBL28089899 | 0.82 | HSP90AB1 (0.47) | CES2CES1BCHEHPGDPDK2 | |
| SCHEMBL2373430 | 0.82 | CES2 (0.59) | CES2CES1BCHEHPGDRXFP1 | |
| SCHEMBL13722818 | 0.82 | CES2 (0.63) | CES2CES1BCHEHPGDALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107892693-A | A kind of preparation method of ticagrelor | 安徽诺全药业有限公司 | 2018-04-10 | — | — | CN | claimed |
| CN-107686447-A | A kind of preparation method of ticagrelor intermediate | 许昌恒生制药有限公司 | 2018-02-13 | — | — | CN | claimed |
| CN-106906249-A | Ticagrelor intermediate and preparation method of mandelate thereof | 辽宁天华生物药业有限公司 | 2017-06-30 | — | — | CN | claimed |
| CN-104744266-B | The preparation method of ticagrelor intermediate | 上虞京新药业有限公司 | 2017-06-27 | — | — | CN | claimed |
| CN-105671099-A | Method for preparing optical pure difluorophenyl ethylene oxide | 中国科学院成都生物研究所 | 2016-06-15 | — | — | CN | claimed |
| CN-102807563-A | Method for preparing voriconazole and intermediate thereof | NANJING HUAWE MEDICAL SCIENCE & TECHNOLOGY DEV CO LTD | 2012-12-05 | — | — | CN | claimed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| EP-4605388-A1 | <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024083933-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | WO | disclosed |
| WO-2021047166-A1 | METHOD FOR SYNTHESIZING TRANYLCYPROMINE INTERMEDIATE | 凯特立斯（深圳）科技有限公司 | 2021-03-18 | — | — | WO | disclosed |
| CN-110627628-A | Beta-iodo-difluoropropanone derivative and preparation method thereof | 上海应用技术大学 | 2019-12-31 | — | — | CN | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20070122741-A1 | Resist protective coating material and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1401819-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020004569-A1 | Polymer, chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2002-01-10 | — | — | US | disclosed |
| US-5104870-A | Psychological disorders | BURROUGHS WELLCOME CO. (US) | 1992-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | CES2 141/4885CES1 155/4885BCHE 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.